KAMPALA, Uganda — 8 November 2026. Uganda and Italy launched PRISMA publicly on 7 November, bringing renewed attention to a €12.75 million programme intended to improve maternal, child and cancer healthcare in northern Uganda. The launch marks a public milestone for an existing funded initiative, rather than the opening of a new hospital.
The University of Milano-Bicocca’s launch notice identifies the university’s BReCHS research centre as coordinator. The project combines clinical services, professional training, research and stronger local health governance. Its central promise is better continuity of care, particularly for vulnerable women and children.
What is Uganda’s PRISMA health project?
PRISMA is an Italy-funded programme supporting maternal, neonatal, child and cancer care in northern Uganda. Its approved grant is €12.75 million. Partners aim to strengthen existing services and reach more than 500,000 people; that target is not a count of patients already treated or services already delivered.
A grant approved before the launch
The Italian cooperation approval record, adopted on 10 December 2025, authorises a €12.75 million grant to the University of Milano-Bicocca for a 36-month initiative. It is grant financing, not a loan obligation described as development assistance.
The approval divides the planned financing between €3 million against 2025 resources, €5 million against 2026 resources and €4.75 million against 2027 resources. It allows the annual distribution to change with implementation. Those allocations should not be read as proof that each amount has already reached a hospital or paid for treatment.
The AICS OpenAID project record lists the programme as ongoing and records the same total commitment. The approved figure is therefore €12.75 million; it should not be confused with a smaller tranche or treated as fresh funding announced entirely in November.
Existing facilities are the delivery route
AVSI’s programme description, published in April 2026, sets out four strands: reproductive and maternal-child care; women’s and paediatric oncology; training and research; and governance, monitoring and evaluation.
INVESTMENT
Uganda’s €12.75m PRISMA Project: Funding and Patient Care
8 nov. 2026
8 nov. 2026
5 min read
Publié
Mis à jour:
KAMPALA, Uganda — 8 November 2026. Uganda and Italy launched PRISMA publicly on 7 November, bringing renewed attention to a €12.75 million programme intended to improve maternal, child and cancer healthcare in northern Uganda. The launch marks a public milestone for an existing funded initiative, rather than the opening of a new hospital.
The University of Milano-Bicocca’s launch notice identifies the university’s BReCHS research centre as coordinator. The project combines clinical services, professional training, research and stronger local health governance. Its central promise is better continuity of care, particularly for vulnerable women and children.
What is Uganda’s PRISMA health project?
PRISMA is an Italy-funded programme supporting maternal, neonatal, child and cancer care in northern Uganda. Its approved grant is €12.75 million. Partners aim to strengthen existing services and reach more than 500,000 people; that target is not a count of patients already treated or services already delivered.
A grant approved before the launch
The Italian cooperation approval record, adopted on 10 December 2025, authorises a €12.75 million grant to the University of Milano-Bicocca for a 36-month initiative. It is grant financing, not a loan obligation described as development assistance.
The approval divides the planned financing between €3 million against 2025 resources, €5 million against 2026 resources and €4.75 million against 2027 resources. It allows the annual distribution to change with implementation. Those allocations should not be read as proof that each amount has already reached a hospital or paid for treatment.
PUBLICITÉ
The AICS OpenAID project record lists the programme as ongoing and records the same total commitment. The approved figure is therefore €12.75 million; it should not be confused with a smaller tranche or treated as fresh funding announced entirely in November.
Existing facilities are the delivery route
AVSI’s programme description, published in April 2026, sets out four strands: reproductive and maternal-child care; women’s and paediatric oncology; training and research; and governance, monitoring and evaluation.
The oncology strand includes planned improvements to screening, early diagnosis and treatment, coordinated with the Uganda Cancer Institute in Gulu. Staff development and academic cooperation form another part of the intervention. These are programme objectives, not evidence that every planned service is already available.
Local reporting from the launch says AVSI’s contribution will cover 32 facilities across 11 administrative areas. They include areas in and around Gulu, Lira, Moroto and Nebbi. The facility count describes planned reach; it does not mean 32 new hospitals have been built.
The programme’s intended beneficiary population exceeds 500,000. Achieving that reach will require working referral systems, staff and community engagement as well as the financing agreement.
Implementation dates need to remain distinct
The public launch came after earlier programme activity. AICS records an actual start of 12 March 2026 and a planned end of 1 February 2029. AVSI’s April description said activity would begin in July, while launch reporting gives a July 2026–June 2029 implementation period.
PUBLICITÉ
These records may describe different administrative and operational stages, but they do not provide a single reconciled timetable. The November event should therefore not be used as the programme’s first day, or as the starting point for an assumed three-year countdown.
For patients, the important dates are more specific: when a facility introduces a service, when equipment becomes usable and when a referral route starts accepting patients. Those milestones will establish delivery more clearly than the launch date alone.
What patients need to know before seeking care
PRISMA’s objectives do not establish a universal entitlement to free treatment at every participating institution. Patients need facility-specific information on screening availability, appointments, referrals, charges and any support for vulnerable households.
A funded programme can strengthen services without replacing all existing hospital rules or fees. Likewise, cancer screening, diagnosis and treatment are different stages of care. Access to one should not be interpreted as a guarantee that every subsequent stage is available at the same location.
Tendances actuelles
PUBLICITÉ
Clear public information will be important as implementation advances. It should identify which services have changed, who can use them and what steps patients must take, rather than offering a general promise of improved healthcare.
The test is sustained care beyond the launch
The project brings together universities, clinical institutions and implementing organisations. That partnership provides a framework for cooperation; its results must still be demonstrated through patient access and quality of care.
Useful measures would include functioning screening services, completed referrals, trained staff applying new skills and fewer interruptions in treatment. These are proposed accountability measures, not outcomes already attributed to PRISMA.
Facility-level delivery schedules, spending information and service instructions will be the next practical evidence of progress. The grant establishes the resources and the launch establishes public commitment. Patients will experience the programme through the care they can actually obtain.
PUBLICITÉ
Articles connexes
